Our previous results showed that erinacine A could be used to investigate in vitro and in vivo antitumor activity through cell cycle arrest in human DLD-1 cancer cells involved in the generation of the ROS activates p70S6K/NFκB pathways, leading to p21 expression. Here, RPS6KB1 is linked to cancer.